Table 1 Baseline clinical characteristics of early IgAN patients
From: Long-term prognosis of clinically early IgA nephropathy is not always favorable
Variables | Values | |||
|---|---|---|---|---|
Age (years) | 26 (20–36) | |||
Sex (male,%) | 60 (43.8%) | |||
Body mass index (kg/m2) | 21.2 (20.0–23.5) | |||
Systolic blood pressure (mmHg) | 120 (110–130) | |||
Serum creatinine (mg/dL) | 0.90 (0.80–1.09) | |||
eGFR (mL/min/1.73 m2) | 85.9 (74.9–100.1) | |||
Proteinuria (g/day) | 0.25 (0.11–0.38) | |||
Serum cholesterol (mg/dL) | 159 (144–185) | |||
Serum albumin (g/dL) | 4.1 (3.9–4.4) | |||
Plasma hemoglobin (g/dL) | 13.2 (12.3–14.4) | |||
Serum IgA (mg/dL) | 302 (223–417) | |||
Follow up duration (months) | 95 (38–207) | |||
RAS blockade (N,%) | 66 (43%) | |||
Glomerulus number | 37 (20–58) | |||
Global sclerosis (%) | 4.0 (0–11.0) | |||
Segmental sclerosis (%) | 0 (0–5.0) | |||
Crescent formation (yes,%) | 14 (9.2%) | |||
WHO grade | I | II | III | IV |
19 (12.4%) | 84 (54.9%) | 37 (24.2%) | 10 (6.5%) | |
None | Mild | Moderate | Severe | |
Mesangial proliferation (yes,%) | 16 (10.7%) | 114 (74.5%) | 16 (10.7%) | 4 (2.6%) |
Tubular atrophy (yes,%) | 43 (28.1%) | 85 (55.6%) | 19 (12.4%) | 2 (1.3%) |
Interstitial fibrosis (yes,%) | 30 (19.6%) | 100 (65.4%) | 17 (11.1%) | 2 (1.3%) |
Interstitial inflammation (yes,%) | 38 (24.8%) | 110 (71.9%) | 1 (0.7%) | 0 (0.0%) |